Radient Pharmaceuticals Corporation

TUSTIN, Calif., Jan. 24, 2012 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In-Vitro Diagnostic (IVD) cancer tests, today announced that its new 2012 Sales, Advertising & Outreach Plan Presentation for its Onko-Sure® cancer test kit is available for investors to view at ... read more

TUSTIN, Calif., Jan. 6, 2012 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced that its new advertising campaign about the effectiveness of Onko-Sure® will be launched with a print ad that will periodically run in ... read more

TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK - News), a developer and marketer of cancer tests, today announces it has expanded its distribution agreement with UniPharma Taiwan headquartered in Taipei, Taiwan. Previously, Radient's agreement with Uni Pharma provided UniPharma the exclusive ... read more

TUSTIN, Calif., Dec. 13, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the launch of a new Onko-Sure website www.onko-sure.com and a new Facebook page and Twitter account. Radient's national marketing campaign currently involves ... read more

TUSTIN, Calif., Dec. 8, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that it has submitted one abstract for the American Society of Colon and Rectal Surgeons' (ASCRS) Annual Meeting to be ... read more

TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that the two abstracts it submitted to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were accepted for presentation from ... read more

TUSTIN, Calif., Dec. 1, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (the "Company") (OTCQX:RXPC), a developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced that all of the holders of its Series B Warrants have exercised such warrants as compelled by the terms thereof, ... read more

TUSTIN, Calif., Nov. 29, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, today announced it has completed restructurings with each of the company's 2011 Noteholders (who hold convertible notes and shares of Series A ... read more

TUSTIN, CA -- (Marketwire) -- 09/20/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has submitted two scientific abstracts to the American Society of Clinical Oncologists (ASCO). Both abstracts discussed ... read more

TUSTIN, CA -- (Marketwire) -- 08/23/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has sold and shipped its first order of Onko-Sure® test kits to a distributor in Brazil. This ... read more

TUSTIN, CA -- (Marketwire) -- 08/11/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has signed a lab partner agreement with New Jersey-based diagnostics laboratory, NeoloMed BioSciences Inc. Onko-Sure® is a ... read more

TUSTIN, CA -- (Marketwire) -- 07/19/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the company will hold its annual shareholder meeting at its corporate headquarters located at 2492 Walnut Avenue, ... read more

TUSTIN, CA -- (Marketwire) -- 07/14/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced today it has selected Regulatory and Clinical Research, Inc. (RCRI) as its specialist consultants on reimbursement and healthcare ... read more

TUSTIN, CA -- (Marketwire) -- 06/08/11 -- Radient Pharmaceuticals Corporation "RPC" (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the filing of its Form 10-Q for the first quarter ended March 31, 2011. "Radient is now putting into place a ... read more

TUSTIN, CA -- (Marketwire) -- 05/24/11 -- Radient Pharmaceuticals Corporation ("RPC") (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of in vitro diagnostic (IVD) cancer tests, announced today, that it intends to file its Annual Report on Form 10-K for the year ... read more

TUSTIN, CA -- (Marketwire) -- 05/18/11 -- Radient Pharmaceuticals Corporation "RPC" (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the Company will exhibit its FDA-cleared Onko-Sure® cancer test at the 47th Annual Meeting of the American Society of Clinical ... read more

TUSTIN, CA -- (Marketwire) -- 05/17/11 -- Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has entered into a settlement agreement with the investors (the "Investors") of the Registered Direct Offering the Company closed in ... read more

TUSTIN, CA -- (Marketwire) -- 04/28/11 -- Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today that, as anticipated, RPC received a letter dated April 25, 2011 from NYSE Amex, LLC (the "Exchange") stating that because RPC, as previously disclosed, did not file its annual report on Form ... read more

TUSTIN, CA -- (Marketwire) -- 04/27/11 -- Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the results of its analysis of data from the U.S. clinical trial conducted in collaboration with a well-recognized, large third-party not-for-profit group practice and its affiliates for RPC's Onko-Sure® in vitro diagnostic ... read more

TUSTIN, CA -- (Marketwire) -- 04/21/11 -- Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today that a Listing Qualifications Panel of the NYSE Amex Committee on Securities (the "Panel") has issued a favorable decision and granted RPC's request for continued listing on the NYSE Amex (the "Exchange") subject ... read more